<DOC>
	<DOCNO>NCT00103831</DOCNO>
	<brief_summary>A phase I-II dose range study BMS-275183 ( oral taxane ) combination pemetrexed ( Alimta ) patient recurrent Non-Small Cell Lung Cancer ( NSCLC ) . The safety efficacy combination study .</brief_summary>
	<brief_title>Oral Taxane Combination With Pemetrexed ( Alimta ) Patients With Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Advanced metastatic pretreated NSCLC Measurable disease Adequate hematologic , hepatic renal function . ECOG Performance Status 02 Inability swallow capsule Recent significant cardiovascular disease Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>NSCLC - non-small cell lung cancer</keyword>
</DOC>